DymistaÃÂ© Nasal Spray with Multifocal Analysis of its Impact on the Rhinitis Disease ExperienceAmtul Salam Sami1* and Nida Ahmed2
- Corresponding Author:
- Dr. Amtul Salam Sami
1 Cow Leaze, E6 6WX, ENT and Allergy Department
Nose and Ear Hospital
University College London Hospitals, London, UK
Tel: 020 7474 2595
E-mail: [email protected]
Received date: August 08, 2014; Accepted date: September 19, 2014; Published date: September 25, 2014
Citation: Sami AS, Ahmed N (2014) Dymista© Nasal Spray with Multifocal Analysis of its Impact on the Rhinitis Disease Experience. Otolaryngol (Sunnyvale) 4:173. doi:10.4172/2161-119X.1000173
Copyright: © 2014 Hutton J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: Rhinitis is a prevalent condition both in primary care and in specialist centres. It has been shown to significantly impact on quality of life. Treatment is often best managed on combined therapies. Dymista© nasal spray is filling a niche for an ‘all in one’ treatment of allergic rhinitis. Method: The MSNOT-20 is a valid disease specific quality of life instrument for rhinitis and rhinosinusitis and it was used to evaluate the symptomatic response to treatment with Dymista nasal spray. Results: Dymista has been shown to improve all domains of the patient experience of rhinitis and rhinosinusitis with positive feedback by both patients and prescribing physicians. Conclusion: Dymista is effective at improving patient symptomatology and improves quality of life. These positive results have opened up further avenues for research to explore its efficiency and place as mode of treatment.